Blood pressure medications have similar results but different side effects

When comparing first-time prescriptions of a single medication for high blood pressure, angiotensin-converting enzyme, or ACE, inhibitors are as effective as angiotensin receptor blockers, or ARBs, in the prevention of cardiovascular events, new research has found. The similarities, however, end with efficacy.

A new study compared the side effects of blood pressure medications. Photo: Wikimedia Commons

In a study that analyzed data from almost 3 million patients, the side effects and safety concerns of these medications were noted and examined. The results showed that patients taking ARBs were less likely to experience serious side effects when compared to patients prescribed ACE inhibitors.

To date, ACE inhibitors are more commonly prescribed. The findings from this research will help doctors tailor blood pressure medications to more closely meet the needs of patients.

Patients taking ACE inhibitors were more likely to develop cough, pancreatic inflammation, gastrointestinal bleeding and fluid accumulation. However, these findings do not include patients taking multiple medications or those already taking ACE inhibitors.

Both medications target the renin-angiotensin-aldosterone system, a group of hormones that act as blood pressure regulators, and block angiotensin to reduce blood vessel constriction.

ACE inhibitors lower blood pressure by blocking an enzyme so less angiotensin is produced, and ARBs block the blood vessel receptors to which angiotensin attaches.

Results from this analysis of first-time therapy may not translate to patients prescribed combination treatments or who switch regimens.

Patients in the study were observed over varying durations of time, and some participants had shortened follow-up periods which could result in less therapeutic effectiveness. (National Science Foundation)

YOU MAY ALSO LIKE

Study evaluates airborne and fomite transmission of SARS-CoV-2

National Institutes of Health scientists studying SARS-CoV-2, the virus that causes COVID-19, have defined in Syrian hamsters how different routes of virus exposure are linked to disease severity.

Monoclonal antibody prevents malaria

One dose of a new monoclonal antibody discovered and developed at the National Institutes of Health safely prevented malaria for up to nine months in people who were exposed to the malaria parasite.

Robotic neck brace can help analyze cancer treatment impacts

New device could help guide recovery after treatment for head and neck cancer.

Serious complications from youth-onset type 2 diabetes arise by young adulthood

People with type 2 diabetes diagnosed during youth have a high risk of developing complications at early ages and have a greater chance of multiple complications within 15 years after diagnosis.

Scientists reverse age-related memory loss

Scientists at Cambridge and Leeds have successfully reversed age-related memory loss in mice and say their discovery could lead to the development of treatments to prevent memory loss in people as they age.

Scientists uncover how decisions about what we see are relayed back through the brain

NIH study in monkeys finds that in visual decision-making, information relevant to the decision is broadcast widely.